Lyfe Capital

MobiDrop develops microfluidic technologies for life sciences and precision medicine. MobiDrop creates cutting-edge instruments, extensive assays, and simple software for ddPCR and single-cell multi-omic platforms. MobiDrop offers ground-breaking solutions for life science research and IVD.

ProfoundBio is an oncology biotherapeutics company focused on the development of novel antibody-based therapeutics with curative potential for patients with cancer.

Starna Therapeutics offers development of innovative drugs with RNA as the core, and has an industry-leading RNA and organ-selective delivery technology platform with independent intellectual property rights; the company has established a rich R&D pipeline , covering infectious disease vaccines, tumor immunity and other fields.

Boyue Bio focuses on the development of biomedical raw materials and integrated solutions. The company's four product lines include Bioactive Materials, Nanometer Microspheres, Chromatographic Products, and Integrated Solutions. Boyue Bio seeks to be a major provider of total solutions and core raw materials for the biomedical industry.

Aspen Neuroscience, Inc. is a private biotechnology company based in San Diego, California, focused on developing innovative therapies for neurological conditions, particularly Parkinson's disease. Established in 2018, the company utilizes induced pluripotent stem cells to create patient-specific restorative cell therapies. Its product pipeline includes ANPD001, an autologous neuron replacement therapy designed for sporadic Parkinson's disease, and ANPD002, a gene-edited version aimed at familial forms of the disease. Aspen Neuroscience combines genomic approaches with stem cell biology to advance its mission of modifying the course of Parkinson's disease through these novel therapeutic strategies.

Elixir Clinical Research is a technology-driven contract research organization (CRO) that specializes in providing comprehensive clinical research services. The company aims to facilitate the rapid launch of new drugs by offering a range of services, including bioequivalence studies, Phase I-IV clinical trials, real-world research, and final application registration. Elixir also supports clients in designing research programs, developing medical strategies, managing regulatory processes, overseeing clinical centers, and handling data management and biostatistics. By delivering qualified and effective clinical research solutions, Elixir assists pharmaceutical companies in navigating the complexities of drug development and regulatory approval.

Molecular Assemblies, Inc. is a San Diego-based company that specializes in enzymatic DNA synthesis technology, which allows for the precise reading and writing of DNA. Founded in 2013, the company targets multiple markets, including life sciences, industrial applications, information storage, nanotechnology, and DNA electronics. Its innovative approach is inspired by natural processes and focuses on producing long, high-quality, sequence-specific DNA in a reliable, affordable, and sustainable manner. The company boasts a strong executive and scientific team and holds an extensive intellectual property portfolio. It has garnered investments from various notable entities, highlighting its potential to advance products in industrial synthetic biology, personalized therapeutics, and precision diagnostics.

MediLink Therapeutics has established its R&D center in Suzhou, China. The company focuses on developing next generation drug conjugates, and aims to serve the vast unmet medical needs in China, and create global value through conducting multicenter clinical trials and cross-border collaborations.

Genepoint Biological Technology (China) Co., Ltd. is a Shanghai-based company that specializes in the manufacturing of devices for cryogenic biomaterial storage and handling. Its product line includes Automated Cryo-Bio Storage systems, Plugged Hybrid Cryo-Storage units, LIN Vapor Freezers, and hoists designed for freezer operations. These products are primarily aimed at life sciences researchers, facilitating the safe and efficient storage of biological materials at low temperatures.

Kyverna Therapeutics, Inc. is a clinical-stage biopharmaceutical company based in Berkeley, California, specializing in the development of cell therapies for serious autoimmune diseases. Founded in 2018, Kyverna employs advanced T cell engineering and synthetic biology technologies to target and eliminate autoreactive immune cells, addressing the root causes of inflammatory diseases. The company is advancing its therapeutic platform with product candidates such as KYV-101, an autologous CD19 CAR T-cell therapy, and KYV-201, an allogeneic version utilizing the same chimeric antigen receptor. Through these innovative approaches, Kyverna aims to provide effective treatments and potential cures for patients suffering from autoimmune conditions.

Shanghai ZhenGe Biotechnology Co.,Ltd. researches and develops drugs. It also engages in mammalian cell line development, upstream development, downstream development, and formulation development for various protein therapeutics. In addition, the company provides contract development and manufacturing services; and offers IND and BLA filing services. Further, it provides platform for research and development of antibodies, transient infection, process development, N-Glycosylation, and CAR-T. Shanghai ZhenGe Biotechnology Co.,Ltd. was founded in 2017 and is based in Shanghai, China.

Edge Medical Robotics, Inc. is a company that specializes in designing and developing advanced surgical equipment. Founded on May 4, 2017, and based in Longgang, Shenzhen, China, the company is dedicated to researching and promoting cutting-edge medical technology. Its mission focuses on enhancing surgical safety and treatment efficacy, aiming to elevate the overall standards of healthcare. Through a commitment to excellence and precision in product development, Edge Medical Robotics strives to contribute positively to the improvement of social health outcomes.

Hangzhou Sciwind Biosciences Co., Ltd. develops and sells protein/peptide drugs for treating diseases in multiple therapeutic areas, including diabetes, obesity, metabolic liver diseases, diabetic retinopathy/macular edema, and neuro-degenerative diseases. The company was founded in 2017 and is based in Hangzhou, China.

HC Scientific Technology Co., Ltd. is a company based in Chengdu, China, that specializes in the development, manufacturing, and distribution of genetic testing instruments, reagents, and software. Founded in 2015, the company serves various sectors, including clinical molecular diagnostics, health genetic testing, and agricultural molecular breeding, both domestically and internationally. HC Scientific's product lineup features instruments such as the Matrix Arrayer for reaction plate preparation, the Matrix Cycler for thermal cycling, and the Matrix Scanner for fluorescence detection. Additionally, the company provides consumables like the Matrix plate and Matrix Mix genotyping reagents, along with a data management system known as Matrix Master. Committed to innovation, HC Scientific focuses on autonomous research and development of its intellectual property, aiming to deliver high-throughput, automated, and cost-effective genetic testing solutions.

ProfoundBio is an oncology biotherapeutics company focused on the development of novel antibody-based therapeutics with curative potential for patients with cancer.

neoX BIOTECH is a biotechnology company that develops antigen-based cancer vaccine through a deep understanding of biophysics and the use of artificial intelligence. It develops a neoantigen prediction and TCR screening platform. The company was founded in 2018 and is based in Beijing, China.

Jianjia Robot develops a hard tissue surgical robot platform promoting technological progress in the field of surgery at home and abroad. Jianjia Robot's orthopedic joint surgical robot, ARTHROBOT, can cover both hip and knee joints, breaking the long-term monopoly of imported surgical robots in this field.

Molecular Assemblies, Inc. is a San Diego-based company that specializes in enzymatic DNA synthesis technology, which allows for the precise reading and writing of DNA. Founded in 2013, the company targets multiple markets, including life sciences, industrial applications, information storage, nanotechnology, and DNA electronics. Its innovative approach is inspired by natural processes and focuses on producing long, high-quality, sequence-specific DNA in a reliable, affordable, and sustainable manner. The company boasts a strong executive and scientific team and holds an extensive intellectual property portfolio. It has garnered investments from various notable entities, highlighting its potential to advance products in industrial synthetic biology, personalized therapeutics, and precision diagnostics.

Abogen Biosciences is a discovery stage biotechnology company focuses on developing nucleic acid-based (RNA and DNA) therapeutics for treatment of cancer and infectious diseases.

Nucleix develops, manufactures, and markets non-invasive molecular cancer diagnostic tests. Its sensitive and specific tests are based on identification of subtle changes in methylation patterns. Nucleix offers a urine test for monitoring of bladder cancer called Bladder EpiCheck and a blood test for early detection of lung cancer called Lung EpiCheck. Adam Wasserstrom, Danny Frumkin, and Elon Ganor founded it in 2008, with its headquarters in Rehovot in Israel.

ImmuneOnco Biopharmaceuticals (Shanghai) Co.,Ltd. develops and commercializes novel cancer immunotherapy products. The company designs platforms to reverse cancer cell-induced immune inhibition and to eradicate cancer cells. It offers platforms harnessing two types of innate immune cells, macrophages and natural killer (NK) cells to fulfill the cancer-killing task. The company’s platforms include Target-Activated NK (TANK™) Cell Therapy, PD-1/PD-L1 antibody blockade assay platform, and Activating Macrophages. The company was founded in 2015 and is headquartered in Shanghai, China.

ABclonal Inc. provides biological research agents and services. Its products include next generation sequencing lib preparation kits, molecular biology products, catalog antibody products, catalog proteins, ELISA kits, and western blot tools and reagents. The company also offers peptide, antibody, and protein services. It provides its products through distributors in Europe, Asia, North America, and Oceania. The company was incorporated in 2016 and is based in Woburn, Massachusetts.

Hangzhou Sciwind Biosciences Co., Ltd. develops and sells protein/peptide drugs for treating diseases in multiple therapeutic areas, including diabetes, obesity, metabolic liver diseases, diabetic retinopathy/macular edema, and neuro-degenerative diseases. The company was founded in 2017 and is based in Hangzhou, China.

Cleveland Diagnostics, Inc. is a company focused on developing and commercializing innovative cancer diagnostics and screening tests. Founded in 2013 and headquartered in Cleveland, Ohio, the company offers a range of non-invasive blood-based tests designed to screen for various types of cancer, including prostate, breast, and ovarian cancer. Cleveland Diagnostics aims to create a new class of diagnostic tests that demonstrate high sensitivity and specificity, enabling early detection of cancer when it is most treatable. The company has formed a strategic collaboration with Genomic Health to further enhance its diagnostic capabilities.

Exegenesis is going to develop new medicine based on gene therapy and focuses on China and the global market. The team consists of experienced professionals, including gene therapy drug design, preclinical studies and clinical development.

Edge Medical Robotics, Inc. is a company that specializes in designing and developing advanced surgical equipment. Founded on May 4, 2017, and based in Longgang, Shenzhen, China, the company is dedicated to researching and promoting cutting-edge medical technology. Its mission focuses on enhancing surgical safety and treatment efficacy, aiming to elevate the overall standards of healthcare. Through a commitment to excellence and precision in product development, Edge Medical Robotics strives to contribute positively to the improvement of social health outcomes.

CANbridge Pharma is a biopharmaceutical company focused on the development and commercialization of healthcare products in China and North Asia, particularly for oncology and rare diseases. Established in 2012 and headquartered in Beijing, with additional offices in Shanghai, Cambridge, Taipei, and Hong Kong, the company partners with Western biopharmaceutical firms to bring clinical-stage pharmaceutical, medical device, and diagnostic products to the region. CANbridge specializes in therapies for serious medical conditions that are either unavailable or inadequately addressed in North Asia. Its key product, CAN008, is a glycosylated CD95-Fc fusion protein aimed at treating glioblastoma multiforme, while the company also has a diverse pipeline of biologics and small molecules targeting conditions such as Hunter Syndrome, hemophilia A, and various rare metabolic disorders. Through licensing and exclusive commercialization agreements, CANbridge seeks to enhance healthcare solutions for underserved patient populations in the region.

Cytek Biosciences provides solutions that enable scientists to rapidly, efficiently obtain deep biological insights through high quality, high parametric datasets. Cytek manufactures and supplies flow cytometry products and services. Cytek’s compact, affordable instruments, and wide-ranging support offerings are used by researchers and clinicians all over the world. Cytek is focused on accelerating the adoption of flow cytometry to fuel scientific discovery. These solutions deliver deep biological insights at an affordable price, provide high-end capabilities, and bring simplified workflows to more researchers than ever before.

ImmuneOnco Biopharmaceuticals (Shanghai) Co.,Ltd. develops and commercializes novel cancer immunotherapy products. The company designs platforms to reverse cancer cell-induced immune inhibition and to eradicate cancer cells. It offers platforms harnessing two types of innate immune cells, macrophages and natural killer (NK) cells to fulfill the cancer-killing task. The company’s platforms include Target-Activated NK (TANK™) Cell Therapy, PD-1/PD-L1 antibody blockade assay platform, and Activating Macrophages. The company was founded in 2015 and is headquartered in Shanghai, China.

Shanghai Shenqi Medical Technology Co., Ltd. specializes in the research, development, production, and sale of minimally invasive vascular interventional products. Established in 2014 and based in Shanghai, the company provides a diverse range of medical devices including releasable embolization systems, peripheral microcatheters, distal access guide catheters, drug-coated coronary balloon catheters, and left atrial appendage occluder systems. These products are designed for various medical applications, including cardiovascular intervention, peripheral vascular intervention, neurovascular intervention, and the treatment of structural heart diseases. Shenqi Medical is committed to delivering innovative solutions for the healthcare industry in China.

Shanghai ZhenGe Biotechnology Co.,Ltd. researches and develops drugs. It also engages in mammalian cell line development, upstream development, downstream development, and formulation development for various protein therapeutics. In addition, the company provides contract development and manufacturing services; and offers IND and BLA filing services. Further, it provides platform for research and development of antibodies, transient infection, process development, N-Glycosylation, and CAR-T. Shanghai ZhenGe Biotechnology Co.,Ltd. was founded in 2017 and is based in Shanghai, China.

Just Medical is an artificial orthopedic implant device and system developer.

HiFiBiO is a biotherapeutics company focused on harnessing the human immune system to address diseases, particularly cancer and autoimmune disorders. Founded in 2013 and based in Paris, the company specializes in proprietary single-cell technologies that facilitate drug and biomarker discovery and development. HiFiBiO's platform combines extensive biological knowledge with advanced single-cell profiling techniques, allowing for the rapid identification and advancement of antibody drugs. Through partnerships with both industry and academic institutions, HiFiBiO aims to promote open innovation and enhance patient outcomes by unlocking the therapeutic potential of the immune system.

Burning Rock Biotech Limited specializes in developing and providing cancer therapy selection tests in China. The company offers a range of 13 next-generation sequencing (NGS)-based tests for various cancers, including lung, gastrointestinal, prostate, breast, and others, utilizing both tissue and liquid biopsy samples. Key products include OncoScreen Plus, which focuses on therapy and immunotherapy selection, and LungPlasma, a liquid biopsy test for non-small cell lung cancer. Additionally, it provides tests like ColonCore for gastrointestinal cancers and HRDCore for assessing genes linked to homologous recombination deficiency. Founded in 2014 and headquartered in Guangzhou, Burning Rock collaborates with major pharmaceutical companies on clinical trials and research, providing central laboratory and companion diagnostics development services. The company aims to offer personalized cancer treatment guidance through its advanced medical and bioinformatics technologies, establishing a comprehensive solution for genetic testing in cancer care.

Aohua Endoscopy Co., Ltd. is a manufacturer of endoscopy equipment and consumables, offering a range of products including imaging processors, endoscopes, and various accessories. The company specializes in solutions for gastroenterology, respiratory care, ear, nose, and throat (E.N.T) applications, as well as veterinary endoscopy. Founded in 1994, Aohua is headquartered in Shanghai, China, and aims to lead in the innovation of endoscope technology while advancing the field of endoscopic diagnosis and treatment.

HiFiBiO is a biotherapeutics company focused on harnessing the human immune system to address diseases, particularly cancer and autoimmune disorders. Founded in 2013 and based in Paris, the company specializes in proprietary single-cell technologies that facilitate drug and biomarker discovery and development. HiFiBiO's platform combines extensive biological knowledge with advanced single-cell profiling techniques, allowing for the rapid identification and advancement of antibody drugs. Through partnerships with both industry and academic institutions, HiFiBiO aims to promote open innovation and enhance patient outcomes by unlocking the therapeutic potential of the immune system.

Ansun BioPharma is a clinical-stage biopharmaceutical company focused on the development of unique host-directed anti-viral. The company is committed to developing safe and effective immuno-biologic therapies to treat the most vulnerable patients. Its founders were ingenious virologists and molecular biologists who realized that targeting a virus is difficult due to the virus’s ability to mutate and avoid the treatment. This ability to mutate also enables the virus to evade vaccines. So instead of trying to hit a moving target, they developed an innovative new approach to fight respiratory viruses: they targeted the host instead of the virus. The company was founded in 2003 and is headquartered in San Diego, California.

Laviana Pharma Co., Ltd. founded in 2005 is a high-tech enterprise. It specializes in providing process and manufacture outsourcing services (CDMO) for the pharmaceutical industry. The main scope of services covers all chemistry-related aspects of process development and transformation for the innovative drug substances and products from laboratory scale to commercialized scale, including process research, process development, process optimization, pilot production and large-scale production of intermediates, API starting materials and API (active pharmaceutical ingredient) for pre-clinical, clinical trial materials and commercialized products. It also provides CMC services for IND and NDA submission of innovative developmental drug. It has three wholly-owned subsidiary, namely, Beijing laviana Pharmatech Co., Ltd., Laviana (Tianjin) Pharmatech Development Co., Ltd., and Laviana Corporation incorporated in United States.

Burning Rock Biotech Limited specializes in developing and providing cancer therapy selection tests in China. The company offers a range of 13 next-generation sequencing (NGS)-based tests for various cancers, including lung, gastrointestinal, prostate, breast, and others, utilizing both tissue and liquid biopsy samples. Key products include OncoScreen Plus, which focuses on therapy and immunotherapy selection, and LungPlasma, a liquid biopsy test for non-small cell lung cancer. Additionally, it provides tests like ColonCore for gastrointestinal cancers and HRDCore for assessing genes linked to homologous recombination deficiency. Founded in 2014 and headquartered in Guangzhou, Burning Rock collaborates with major pharmaceutical companies on clinical trials and research, providing central laboratory and companion diagnostics development services. The company aims to offer personalized cancer treatment guidance through its advanced medical and bioinformatics technologies, establishing a comprehensive solution for genetic testing in cancer care.

Burning Rock Biotech Limited specializes in developing and providing cancer therapy selection tests in China. The company offers a range of 13 next-generation sequencing (NGS)-based tests for various cancers, including lung, gastrointestinal, prostate, breast, and others, utilizing both tissue and liquid biopsy samples. Key products include OncoScreen Plus, which focuses on therapy and immunotherapy selection, and LungPlasma, a liquid biopsy test for non-small cell lung cancer. Additionally, it provides tests like ColonCore for gastrointestinal cancers and HRDCore for assessing genes linked to homologous recombination deficiency. Founded in 2014 and headquartered in Guangzhou, Burning Rock collaborates with major pharmaceutical companies on clinical trials and research, providing central laboratory and companion diagnostics development services. The company aims to offer personalized cancer treatment guidance through its advanced medical and bioinformatics technologies, establishing a comprehensive solution for genetic testing in cancer care.